Your browser is no longer supported. Please, upgrade your browser.
Settings
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.75 Insider Own1.50% Shs Outstand80.50M Perf Week-3.56%
Market Cap524.06M Forward P/E- EPS next Y-0.70 Insider Trans-1.59% Shs Float79.34M Perf Month-23.50%
Income-55.10M PEG- EPS next Q-0.19 Inst Own73.50% Short Float14.20% Perf Quarter9.41%
Sales26.40M P/S19.85 EPS this Y-26.80% Inst Trans-0.06% Short Ratio6.53 Perf Half Y55.74%
Book/sh0.02 P/B325.50 EPS next Y-2.90% ROA-60.20% Target Price8.38 Perf Year93.75%
Cash/sh0.68 P/C9.60 EPS next 5Y19.90% ROE-471.80% 52W Range2.49 - 9.25 Perf YTD2.84%
Dividend- P/FCF- EPS past 5Y9.90% ROI-87.90% 52W High-29.62% Beta3.48
Dividend %- Quick Ratio1.20 Sales past 5Y6.10% Gross Margin91.30% 52W Low161.45% ATR0.37
Employees65 Current Ratio1.20 Sales Q/Q95.70% Oper. Margin- RSI (14)35.70 Volatility4.20% 4.77%
OptionableYes Debt/Eq33.56 EPS Q/Q75.30% Profit Margin- Rel Volume0.42 Prev Close6.61
ShortableYes LT Debt/Eq15.94 EarningsFeb 27 BMO Payout- Avg Volume1.73M Price6.51
Recom2.40 SMA20-15.21% SMA50-11.94% SMA20018.10% Volume722,848 Change-1.51%
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Nov-11-15Downgrade BofA/Merrill Neutral → Underperform
Oct-09-15Downgrade BofA/Merrill Buy → Neutral
Sep-09-15Initiated Jefferies Hold
Jun-30-15Upgrade BofA/Merrill Neutral → Buy $12 → $19
Apr-21-15Initiated FBR Capital Outperform $18
Apr-20-15Upgrade BofA/Merrill Underperform → Neutral $8 → $12
May-30-14Reiterated H.C. Wainwright Buy $21 → $24
Mar-04-14Reiterated MLV & Co Buy $9 → $15
Feb-28-14Initiated Oppenheimer Perform
Feb-20-14Initiated Mizuho Buy $23
Feb-18-14Initiated Needham Buy $14
Apr-13-17 12:13PM  After announcing a $45M public offering, BioCryst to launch new trial American City Business Journals
Apr-12-17 06:45AM  BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks GlobeNewswire -5.68%
Apr-04-17 10:50AM  BioCryst to receive royalties from cancer treatment approved in Japan American City Business Journals
10:50AM  BioCryst to receive royalties from cancer treatment approved in Japan
Apr-03-17 12:55PM  Stocks of companies with Raleigh-Durham area HQ make a comeback in March at bizjournals.com
12:55PM  Stocks of companies with Raleigh-Durham area HQ make a comeback in March American City Business Journals
07:18AM  BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan GlobeNewswire
Mar-29-17 06:52AM  BioCryst to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-21-17 09:32AM  Biotech Premarket Movers: Esperion, Minerva and BioCryst -9.89%
Mar-20-17 01:29PM  Wait for the Pullback on BioCryst Pharmaceuticals TheStreet.com
01:29PM  Wait for the Pullback on BioCryst Pharmaceuticals
Mar-19-17 01:51PM  Don't Let Offerings Blindside Your Thesis Benzinga
01:51PM  Don't Let Offerings Blindside Your Thesis
Mar-17-17 05:01PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
09:58AM  Teva Launches Authorized Generic of Allergan's Minastrin
Mar-15-17 03:47PM  AstraZeneca's Cancer Drug Lynparza Positive in Phase III
10:36AM  BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue? Zacks
10:36AM  BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?
06:13AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-14-17 09:28AM  Its time to vaccinate your investments against a deadly bird flu MarketWatch
09:28AM  Its time to vaccinate your investments against a deadly bird flu at MarketWatch
Mar-09-17 08:21PM  BioCryst Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire
10:07AM  Biotech Premarket Movers: Spectrum, BioCryst, Curis
Mar-08-17 04:58PM  The Reason Behind BioCryst Pharmaceuticals, Inc.'s 12% Pop Higher at Motley Fool +8.38%
04:01PM  BioCryst Pharmaceuticals Commences Public Offering of Common Stock GlobeNewswire
08:15AM  Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session
Mar-07-17 01:47PM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
Mar-03-17 01:04PM  BIOCRYST PHARMACEUTICALS INC Financials
09:30AM  Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta Therapeutics and BioCryst Pharmaceuticals Accesswire
Mar-01-17 09:40AM  BioCryst Pharmaceuticals, Inc. (BCRX): A Discount Entry? at Insider Monkey +9.94%
Feb-28-17 05:32PM  Here's Why BioCryst Pharmaceuticals Inc. Catapulted Higher by as Much as 17% at Motley Fool +13.25%
12:25PM  BioCryst 4Q Net 6 Cents a Share Beats Street at Investopedia
Feb-27-17 11:25PM  Edited Transcript of BCRX earnings conference call or presentation 27-Feb-17 2:00pm GMT
10:02AM  BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns
09:09AM  Biotech Premarket Movers: BioCryst, Sangamo, Cempra
07:51AM  BioCryst Pharmaceuticals Stock Drops After Reporting 4Q Loss
07:40AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
07:07AM  Q4 2016 BioCryst Pharmaceuticals Inc Earnings Release - Before Market Open
06:31AM  BioCryst reports 4Q loss
06:15AM  BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
06:00AM  BioCryst Reports Positive Interim Results from its APeX-1 Trial GlobeNewswire
Feb-17-17 08:34AM  Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?
07:52AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : February 17, 2017
Feb-16-17 07:40AM  Coverage initiated on BioCryst Pharma by Ladenburg Thalmann +6.82%
Feb-15-17 07:03AM  BioCryst to Announce Fourth Quarter and Year End 2016 Financial Results February 27 GlobeNewswire +6.57%
Jan-31-17 09:29AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : January 31, 2017
Jan-30-17 02:55PM  BioCryst plans for European launch of injectable flu therapy at bizjournals.com -6.36%
08:06AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:45AM  BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency GlobeNewswire
Jan-25-17 08:56AM  Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?
Jan-23-17 11:33AM  BioCryst Pharmaceuticals, Inc. Value Analysis (NASDAQ:BCRX) : January 23, 2017
Jan-20-17 12:55PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : January 20, 2017
07:13AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : January 20, 2017
Jan-09-17 06:04AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -11.08%
Jan-08-17 03:30PM  BioCryst Receives Health Canada Approval for RAPIVAB® for the Treatment of Influenza GlobeNewswire
Jan-04-17 06:45AM  BioCryst to Present at the J.P. Morgan Healthcare Conference GlobeNewswire +8.18%
Dec-29-16 04:36AM  Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)?
Dec-22-16 08:40AM  Are Options Traders Betting on a Big Move in BioCryst (BCRX) Stock?
Dec-19-16 10:45AM  Finally Getting Back to a Stock Picker's Market +10.66%
Dec-16-16 03:14PM  A Trump Presidency May Be Good for Biotech +11.13%
11:46AM  Shark Bites: What, Market Worry?
11:12AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 16, 2016
Dec-05-16 11:50AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : December 5, 2016
08:48AM  What Smart Money Thinks about BioCryst Pharmaceuticals, Inc. (BCRX)? at Insider Monkey
Nov-23-16 12:42PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 23, 2016
Nov-22-16 10:42AM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-17-16 07:05AM  BioCryst to Present at the Piper Jaffray Healthcare Conference November 30 GlobeNewswire
Nov-10-16 07:14AM  How investors are playing Biocryst
Nov-09-16 12:29PM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : November 9, 2016 +7.49%
Nov-08-16 02:26PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
07:52AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : November 8, 2016
Nov-07-16 12:29PM  Edited Transcript of BCRX earnings conference call or presentation 7-Nov-16 4:00pm GMT +14.83%
08:02AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclos
07:07AM  Q3 2016 BioCryst Pharmaceuticals Inc Earnings Release - Before Market Open
06:56AM  BioCryst reports 3Q loss
06:48AM  BioCryst Reports Third Quarter 2016 Financial Results GlobeNewswire
Oct-26-16 02:50PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:30PM  BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016 GlobeNewswire
Oct-24-16 02:40PM  BioCryst to Announce Third Quarter 2016 Financial Results November 7 GlobeNewswire
Oct-21-16 08:14AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US : October 21, 2016
Oct-19-16 11:02AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : October 19, 2016
Oct-10-16 08:38AM  BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US : October 10, 2016
Sep-26-16 07:26AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fin
06:47AM  BioCryst Closes $23 Million Senior Credit Facility GlobeNewswire
Sep-22-16 01:10PM  5 Stocks Under $10 That Could Make You a Lot of Money
Sep-21-16 10:18AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : September 21, 2016
Sep-07-16 01:51PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +12.11%
06:58AM  BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model GlobeNewswire
Aug-31-16 02:40PM  BioCryst to Present at the Baird 2016 Global Healthcare Conference September 8 GlobeNewswire
Aug-29-16 11:04AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : August 29, 2016
Aug-23-16 08:04AM  Biocryst Pharmaceuticals Inc (BCRX): Billionaire David E. Shaws Fund Increases Stake at Insider Monkey
Aug-17-16 10:02AM  Biocryst Pharmaceuticals Inc (BCRX): Baker Bros. Advisors Unloads Nearly 4 Million Shares at Insider Monkey
Aug-15-16 10:13AM  ETFs with exposure to BioCryst Pharmaceuticals, Inc. : August 15, 2016 -6.35%
Aug-12-16 12:36PM  BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-11-16 12:05PM  Here's the Buzz Behind BioCryst Pharmaceuticals, Inc.'s 27% Gain in July at Motley Fool
10:28AM  BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:18AM  BioCryst Announces Initiation of the APeX-1 Clinical Trial of BCX7353 for Hereditary Angioedema GlobeNewswire
Aug-10-16 01:24PM  Bulls pile into Biocryst Pharmaceuticals
08:15AM  BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 18.1%
Aug-08-16 03:42PM  BIOCRYST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea; Seqirus UK Limited for the development and commercialization of RAPIVAB worldwide, except Japan, Taiwan, Korea, and Israel; and the University of Alabama at Birmingham for the development of influenza neuraminidase and complement inhibitors. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STAAB THOMAS R IISenior Vice President and CFOMar 20Option Exercise3.783,25012,285144,710Mar 22 10:40 AM
STAAB THOMAS R IISenior Vice President and CFOMar 20Sale9.203,25029,900141,460Mar 22 10:40 AM
STAAB THOMAS R IISenior Vice President and CFOMar 16Option Exercise2.9736,455108,300153,768Mar 20 03:01 PM
STAAB THOMAS R IISenior Vice President and CFOMar 10Option Exercise3.783,25012,285120,563Mar 14 01:47 PM
STAAB THOMAS R IISenior Vice President and CFOMar 10Sale9.063,25029,445117,313Mar 14 01:47 PM
STAAB THOMAS R IISenior Vice President and CFOMar 08Option Exercise3.786,50024,570123,813Mar 10 04:19 PM
STAAB THOMAS R IISenior Vice President and CFOMar 08Sale8.436,50054,763117,313Mar 10 04:19 PM
STAAB THOMAS R IISenior Vice President and CFOMar 06Option Exercise3.783,25012,285120,563Mar 08 08:05 AM
STAAB THOMAS R IISenior Vice President and CFOMar 06Sale7.903,25025,675117,313Mar 08 08:05 AM
STAAB THOMAS R IISenior Vice President and CFODec 19Option Exercise3.783,25012,285127,437Dec 21 10:42 AM
STAAB THOMAS R IISenior Vice President and CFODec 19Sale7.453,25024,213124,187Dec 21 10:42 AM
Barnes Alane PVP, General Counsel & Corp SecSep 14Sale4.278,35735,68479,377Sep 16 10:54 AM
Babu Yarlagadda SSenior VP - Drug DiscoveryAug 25Sale4.0630,000121,800111,428Aug 29 10:46 AM
BAKER BROS. ADVISORS LP10% OwnerAug 16Sale4.299904,2461,551,387Aug 16 06:11 PM
BAKER BROS. ADVISORS LP10% OwnerAug 15Sale4.83400,0001,931,0401,551,527Aug 16 06:11 PM
STAAB THOMAS R IISenior Vice President and CFOAug 12Sale5.224,55823,793124,187Aug 15 02:07 PM
BAKER BROS. ADVISORS LP10% OwnerAug 12Sale5.023,645,60018,315,8171,607,944Aug 16 06:11 PM
STAAB THOMAS R IISenior Vice President and CFOAug 11Sale5.051,3066,595128,745Aug 15 02:07 PM
STAAB THOMAS R IISenior Vice President and CFOAug 09Sale4.4314,57764,576130,051Aug 11 01:53 PM